Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
49
INCY Quote, Financials, Valuation and Earnings
Last price:
$69.19
Seasonality move
:
3.41%
Day range:
$69.25 - $70.12
52-week range:
$50.35 - $83.95
Dividend yield:
0%
P/E ratio:
496.86x
P/S ratio:
3.70x
P/B ratio:
4.23x
Volume:
764.5K
Avg. volume:
2.3M
1-year change:
11.21%
Market cap:
$13.4B
Revenue:
$3.7B
EPS (TTM):
$0.14
Analysts' Opinion
-
Consensus RatingIncyte has received a consensus rating of Hold. The company's average rating is a Hold based on 10 Buy ratings, 14 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $79.38, Incyte has an estimated upside of 14.12% from its current price of $69.56.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $52.00 representing 100% downside risk from its current price of $69.56.
Fair Value
-
According to the consensus of 24 analysts, Incyte has 14.12% upside to fair value with a price target of $79.38 per share.
INCY vs. S&P 500
-
Over the past 5 trading days, Incyte has overperformed the S&P 500 by 1.16% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Incyte does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Incyte has grown year-over-year revenues for 26 quarters straight. In the most recent quarter Incyte reported revenues of $1.1B.
Earnings Growth
-
Incyte earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Incyte reported earnings per share of $0.54.
Enterprise value:
11.6B
EV / Invested capital:
3.67x
Price / LTM sales:
3.70x
EV / EBIT:
42.04x
EV / Revenue:
2.85x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
691.95x
Price / Operating cash flow:
898.04x
Enterprise value / EBITDA:
31.87x
Gross Profit (TTM):
$3.8B
Return On Assets:
0.54%
Net Income Margin (TTM):
0.8%
Return On Equity:
0.75%
Return On Invested Capital:
0.75%
Operating Margin:
14.9%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $3.3B | $3.6B | $4.1B | $919M | $1.1B | |
| Gross Profit | $3.1B | $3.4B | $3.8B | $858.9M | $1.1B | |
| Operating Income | $609.5M | $541.9M | $6.1M | $214.3M | $169.5M | |
| EBITDA | $635.8M | $725.4M | $364.8M | $255.8M | $179.8M | |
| Diluted EPS | $3.93 | $1.89 | $0.14 | $0.76 | $0.54 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.2B | $2.9B | $3.8B | $4.4B | $2.8B | |
| Total Assets | $3.3B | $4.2B | $5.5B | $6.4B | $5B | |
| Current Liabilities | $606.2M | $742.7M | $1B | $1.1B | $1.5B | |
| Total Liabilities | $916.6M | $1.1B | $1.3B | $1.5B | $1.8B | |
| Total Equity | $2.4B | $3.1B | $4.2B | $4.9B | $3.2B | |
| Total Debt | $11.9M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $801.6M | $632.4M | $101.8M | $147.8M | $310.9M | |
| Cash From Investing | -$123.7M | -$74.1M | $24.5M | -$17.2M | $38.3M | |
| Cash From Financing | $10.7M | -$22.9M | -$2B | -$37.3M | -$32.4M | |
| Free Cash Flow | $710.6M | $565.9M | $16.8M | $136.9M | $293.2M | |
INCY
Sector
Market Cap
$13.4B
$46.5M
Price % of 52-Week High
82.86%
47.23%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
11.21%
-31.38%
Beta (5-Year)
0.686
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$69.01
200-day SMA
Buy
Level
$63.44
Bollinger Bands (100)
Buy
Level
62.84 - 73.92
Chaikin Money Flow
Buy
Level
239.7M
20-day SMA
Sell
Level
$71.46
Relative Strength Index (RSI14)
Sell
Level
44.49
ADX Line
Buy
Level
11.32
Williams %R
Neutral
Level
-68.1145
50-day SMA
Sell
Level
$72.46
MACD (12, 26)
Sell
Level
-1.19
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
131.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.8944)
Buy
CA Score
(Annual)
Level (1.5437)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-3.9052)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Stock Forecast FAQ
In the current month, INCY has received 10 Buy ratings 14 Hold ratings, and 0 Sell ratings. The INCY average analyst price target in the past 3 months is $79.38.
-
Where Will Incyte Stock Be In 1 Year?
According to analysts, the consensus estimate is that Incyte share price will rise to $79.38 per share over the next 12 months.
-
What Do Analysts Say About Incyte?
Analysts are divided on their view about Incyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Incyte is a Sell and believe this share price will drop from its current level to $52.00.
-
What Is Incyte's Price Target?
The price target for Incyte over the next 1-year time period is forecast to be $79.38 according to 24 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 14 analysts rate the stock a Hold.
-
Is INCY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Incyte is a Hold. 14 of 24 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of INCY?
You can purchase shares of Incyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Incyte shares.
-
What Is The Incyte Share Price Today?
Incyte was last trading at $69.19 per share. This represents the most recent stock quote for Incyte. Yesterday, Incyte closed at $69.56 per share.
-
How To Buy Incyte Stock Online?
In order to purchase Incyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 5.95% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 7.5% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 4.31% over the past day.
